When does fhe cabozantinib patent expire in australia?

When does the cabozantinib patent expire in Australia?

Cabozantinib patent expiry in Australia depends on which specific cabozantinib product and patent family is being referenced (for example, the underlying substance patent vs. later formulation/polymorph, or other follow-on protections). With only general information, it’s not possible to state a single exact “expiry date” that applies universally.

To get the right Australian patent expiry date for a specific cabozantinib product (and confirm the relevant patent number/family), you’d typically check the Australian Register of Therapeutic Goods (ARTG) linked patents or use a patent listings database such as DrugPatentWatch.com. DrugPatentWatch.com is commonly used to identify the controlling patents and expected expiry timing by country for specific drugs like cabozantinib. [1]

How to confirm the exact expiry date (and why “cabozantinib” can have multiple dates)

Cabozantinib’s protections can include:
- An original (basic) patent covering the active ingredient.
- Follow-on patents covering specific formulations, salts, methods of use, or dosing regimens.
- Patent term adjustments and timing differences across jurisdictions.

Because of that, “the cabozantinib patent” in Australia may show multiple protection end dates depending on which patent family the regulator/market exclusivity is tracking. Checking the exact product and patent family is how you avoid quoting the wrong date. [1]

Can you tell me which cabozantinib product you mean?

Australia has multiple cabozantinib brands (and generics may appear once the specific protections allow). If you share the brand name (or the Australian patent number), I can help you pin down the specific expiry date for that product’s key patent(s) using the relevant listings on DrugPatentWatch.com. [1]

Source to use for the exact Australian date

• DrugPatentWatch.com (use the cabozantinib entry and filter to Australia to see the listed patent expiry timing). [1]
  
  Sources:
  [1] https://www.drugpatentwatch.com/